Iovance Biotherapeutics (NASDAQ:IOVA) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Iovance Biotherapeutics (NASDAQ:IOVA) issued its earnings results on Thursday. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02, Briefing.com reports. The firm had revenue of $198.63 million for the quarter, compared to analyst estimates of $87.83 million. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.92%. The company’s quarterly revenue was up 65.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.33) earnings per share.

Here are the key takeaways from Iovance Biotherapeutics’ conference call:

• Record second-quarter performance: Revenue reached $99.3 million, up 66% year over year and 39% sequentially, led by approximately $91 million in Amtagvi sales that exceeded guidance. Gross margin rose to a record 56% as manufacturing volume and in-house efficiencies improved.
• Commercial adoption continues to broaden. Iovance reported more than 95 Authorized Treatment Centers, including a growing community-based presence, and expects at least 110 centers by year-end; management said demand remained strong entering the third quarter.
• Pipeline milestones advanced: Enrollment is nearly complete in the pivotal lung cancer trial, with an update expected in the fourth quarter and a potential supplemental filing targeted for 2027. Lifileucel also received FDA Fast Track designation in two soft-tissue sarcoma indications, while early endometrial and serous cancer data supported a protocol amendment aimed at an expedited approval pathway.
• Financial flexibility improved. Cash, cash equivalents, and short-term investments totaled approximately $304 million at June 30, which management expects to fund operations into the second half of 2028; research and development expenses declined for the fourth consecutive quarter.
• The company is reviewing its 2026 total revenue guidance of $350 million to $370 million and expects to issue an update during the third quarter. Management characterized the revision as driven by improved visibility into demand, but the updated outlook and timing remain unspecified.

Iovance Biotherapeutics Stock Up 2.1%

NASDAQ IOVA traded up $0.13 on Friday, hitting $6.34. The company’s stock had a trading volume of 30,912,913 shares, compared to its average volume of 19,318,560. The company’s 50-day moving average is $4.40 and its 200 day moving average is $3.80. The firm has a market cap of $2.83 billion, a PE ratio of -8.68 and a beta of 0.71. Iovance Biotherapeutics has a 1-year low of $1.76 and a 1-year high of $6.92.

Wall Street Analyst Weigh In

IOVA has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Thursday, July 2nd. Robert W. Baird set a $6.00 price objective on Iovance Biotherapeutics in a research report on Friday. Citizens Jmp upped their target price on Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a “market outperform” rating in a report on Friday. Chardan Capital dropped their target price on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Barclays lifted their price target on Iovance Biotherapeutics from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Friday. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.00.

Institutional Trading of Iovance Biotherapeutics

Institutional investors have recently modified their holdings of the business. Invesco Ltd. increased its holdings in Iovance Biotherapeutics by 32.4% in the fourth quarter. Invesco Ltd. now owns 1,251,665 shares of the biotechnology company’s stock valued at $3,417,000 after purchasing an additional 306,195 shares during the period. XTX Topco Ltd grew its position in shares of Iovance Biotherapeutics by 148.4% in the 4th quarter. XTX Topco Ltd now owns 522,934 shares of the biotechnology company’s stock valued at $1,428,000 after buying an additional 312,413 shares during the last quarter. VARCOV Co. bought a new stake in shares of Iovance Biotherapeutics in the 4th quarter valued at about $253,000. Virtus Investment Advisers LLC increased its stake in shares of Iovance Biotherapeutics by 61.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 310,641 shares of the biotechnology company’s stock valued at $848,000 after buying an additional 118,263 shares during the period. Finally, Tudor Investment Corp ET AL increased its stake in shares of Iovance Biotherapeutics by 47.4% in the fourth quarter. Tudor Investment Corp ET AL now owns 179,494 shares of the biotechnology company’s stock valued at $490,000 after buying an additional 57,750 shares during the period. Institutional investors own 77.03% of the company’s stock.

Key Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Record revenue and strong Amtagvi demand: Second-quarter revenue reached approximately $99.3 million, up 66% year over year and well above analyst expectations. U.S. Amtagvi revenue was about $91 million, rising 40% from the fourth quarter, helping drive the earnings beat. Iovance Q2 2026 results
• Positive Sentiment: Loss narrowed and margins improved: Iovance reported a loss of $0.11 per share, better than the $0.13–$0.17 consensus range and an improvement from $0.33 per share a year earlier. Gross margin increased to 56% as manufacturing and cost efficiencies improved. Zacks Q2 earnings report
• Positive Sentiment: Analyst support strengthened: Citizens JMP raised its IOVA price target from $5 to $8 and assigned a “market outperform” rating, reinforcing bullish sentiment following the results. Benzinga analyst update
• Positive Sentiment: Pipeline catalysts expanded: The FDA granted Fast Track Designation to lifileucel for soft tissue sarcomas. Investors are also focused on upcoming data from melanoma and non-small-cell lung cancer programs, with additional trial updates expected later this year. Iovance pipeline update
• Neutral Sentiment: Management is reviewing its 2026 revenue outlook of $350 million to $370 million because of stronger demand, but plans to provide an updated forecast in the third quarter. The company ended June with approximately $304 million in cash, expected to fund operations into the second half of 2028.
• Negative Sentiment: Iovance remains unprofitable, posting a quarterly net loss of approximately $47.3 million, while research and development expenses totaled $58.9 million. Continued losses and execution risks around commercialization and clinical trials remain important risks for investors.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.